BIO-Windhover Conference Attracts More Than 160 Companies

WASHINGTON, D.C. (April 18, 2002) - More than 250 representatives from more than 160 companies have registered to attend the first BIO-Windhover Partnering Conference. The Biotechnology Industry Organization (BIO) has teamed with a leading health-care business information provider, Windhover Information, to host this biotechnology partnering conference.

The goal of BIO-Windhover is to bring together pharmaceutical and biotech decision makers in a format designed to provide maximum opportunity for focused partnering discussions. Already more than 200 meetings from close to 1,000 requests have been scheduled between life-science executives. In addition to pre-scheduled meetings, on-site partnering facilitation and networking receptions, the conference will feature four plenary sessions and panels on the most pressing issues facing business development professionals.

The partnering event will be held at the Ritz-Carlton in Washington, April 24-26, and will feature senior partnering delegations life-sciences companies, including Amgen, AstraZeneca, Aventis, Baxter, Bristol-Myers Squibb, Genentech, Genzyme, GlaxoSmithKline, Novartis, Pfizer, Schering-Plough and Wyeth Pharmaceuticals. For a complete list of participating companies, visit the BIO-Windhover section of or the meeting Web site at

The Future of Pharmaceutical Research: Challenges and Solutions
WHEN: Thursday, April 25, 8:30 - 10 a.m.
WHO: Robert Tepper, chief scientific officer and executive vice president of discovery at Millennium Pharmaceuticals Inc.
Goran Ando, president of research and development at Pharmacia Corp.
Richard DiMarchi, group vice president of research technologies at Eli Lilly and Co.
William Haseltine, chairman and CEO of Human Genome Sciences Inc.
Roger Longman, managing partner of Windhover Information
WHERE: Ritz-Carlton, Ballroom Salon 1

VC, Fund Manager, and Big Pharma Perspective
WHEN: Thursday, April 25, 1:30 - 3 p.m.
WHO: Scott Sacane, managing director of
Michael Lytton, general partner at Oxford Bioscience Partners
Nicholas Galakatos, general partner at MPM Capital
Karen Bernstein, chairman and editor-in-chief of BioCentury
Gary Pinkus, partner at McKinsey & Company
Jim Flynn, partner at Deerfield Management
WHERE: Ritz-Carlton, Ballroom Salon 3

Due Diligence: What Can Be Done?
WHEN: Friday, April 26, 8:30 - 10 a.m.
WHO: Robert P. Brady, partner at Hogan & Hartson, LLP
John Doll, director of technology center 1600 at the U.S. Patent & Trademark Office
Sam Saks, company group chairman at Alza Corporation (a division of Johnson & Johnson)
Christine de los Reyes, senior director of licensing and development at Pfizer, Inc.
WHERE: Ritz-Carlton, Ballroom Salon 1

Business Development: Emerging Patterns in Platform, Discovery & Clinical-Phase Deal Structures
WHEN: Friday, April 26, 10:30 a.m. - noon
WHO: Arlene Morris, president and CEO of Clearview Projects, Inc.
Bob Jones, partner at Cooley Godward, LLP
Steve Holtzman, president and CEO of Infinity Pharmaceuticals
Stelios Papadopoulos, managing director of SG Cowen Securities Corporation
Scott Morrison national director of life sciences at Ernst & Young
WHERE: Ritz-Carlton, Ballroom Salon 1

Press registration is complimentary for credentialed members of the news media. Registration and other information can be found at Contact Carrie Housman at (202) 962-9200 with any media questions.

BIO represents more than 1,000 biotechnology companies, academic institutions, state
biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.

# # #